20 March 2016 - Cost regulators for the National Health Service in England and Wales have reiterated their support for the use of Novartis’ revolutionary heart drug Entresto to treat patients with a certain type of heart failure.

In final draft guidance, the National Institute for Health and Care Excellence has recommended the drug as an option for treating symptomatic chronic heart failure with reduced ejection fraction in adult patients with New York Heart Association class II to IV symptoms, but restricting its use to those with a left ventricular ejection fraction of 35% or less.

For more details, go to: http://www.pharmatimes.com/Article/16-03-20/NICE_confirms_support_for_Novartis_heart_drug_Entresto.aspx